Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells

Fig. 6

Guadecitabine/ICBs shift towards a Th1 response and inhibit angiogenesis and metastatization. Cytokines level expressed in pg/ml detected by Milliplex assay correlated to: A Th1 responses, B Th2 responses, C angiogenesis and metastasization (CXCL5) regulation and D upper row: MDSC generation and activation, D lower row: MDSC and leukocyte migration (n=3-5 mice/group). *p<0.05, **p<0.02

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us